\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ multiple\\ pumonary\\ nodules\\ which\\ show\\ increased\\ metabolic\\ activity\\ on\\ pet\\.\ \(0\)\
\-\ uterine\\ leiomyosarcom\\ with\\ pulmonary\\ metastasis\ \(0\)\
\-\ thromboemboli\\ with\\ organizing\\ infarcts\ \(0\)\
\-\ septic\\ emboli\ \(22\)\
\-\ wegener\\ granulomatosis\ \(0\)\
\-\ malignancy\\:\ \(1\)\
\-\ \\ \\ \\ metastases\\(breast\\,renal\\,gi\\,uterus\\,ovary\\,sarcoma\\)\\,lymphoma\\,\ \(0\)\
\-\ \\ \\ \\ multiple\\ primary\\ bronchgenic\\ ca\ \(0\)\
\-\ benign\\:\ \(2\)\
\-\ \\ \\ \\ hamartoma\\,benign\\ mets\\ leimyoma\\ av\\ malformation\\,\\ amyloidosis\ \(0\)\
\-\ history\\ of\\ large\\ symptomatic\\ uterine\\ fibroids\\.patient\\ elected\\ for\\ uterine\\ artery\\ embolization\\ \\(uae\\)\\ as\\ treatment\\ modality\\.\\ 18\\ months\\ after\\ uae\\ develop\\ sob\\/cough\\.\ \(0\)\
\-\ uterine\\ leiomysarcoma\\ can\\ arise\\ independent\\ of\\ leiomyoma\\(fibroids\\)as\\ well\\ as\\ occuring\\ with\\ sarcomatous\\ transformation\\ of\\ preexisitng\\ leiomyoma\\(reported\\ between\\ 1\\%\\-02\\%\\ of\\ pathology\\ specimens\\ from\\ uteruses\\ removed\\ for\\ symptomatic\\ leiomyomas\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ uterine\\:\\ 0\\.14376070902043228\ \(0\)\
\-\ uae\\:\\ 0\\.13315362694109104\ \(0\)\
\-\ leiomyoma\\:\\ 0\\.08248079983685634\ \(0\)\
\-\ leiomyosarcom\\:\\ 0\\.07225834773743031\ \(0\)\
\-\ bronchgenic\\:\\ 0\\.07225834773743031\ \(0\)\
\-\ fibroids\\.patient\\:\\ 0\\.07225834773743031\ \(0\)\
\-\ sob\\/cough\\:\\ 0\\.07225834773743031\ \(0\)\
\-\ leiomysarcoma\\:\\ 0\\.07225834773743031\ \(0\)\
\-\ preexisitng\\:\\ 0\\.07225834773743031\ \(0\)\
\-\ \\-02\\:\\ 0\\.07225834773743031\ \(0\)\
\-\ pumonary\\:\\ 0\\.06657681347054552\ \(0\)\
\-\ leimyoma\\:\\ 0\\.06657681347054552\ \(0\)\
\-\ uteruses\\:\\ 0\\.06657681347054552\ \(0\)\
\-\ thromboemboli\\:\\ 0\\.060895279203660724\ \(0\)\
\-\ independent\\:\\ 0\\.059066233701085234\ \(0\)\
\-\ symptomatic\\:\\ 0\\.055655465978593645\ \(0\)\
\-\ leiomyomas\\:\\ 0\\.05521374493677592\ \(0\)\
\-\ organizing\\:\\ 0\\.05424831021828097\ \(0\)\
\-\ sarcomatous\\:\\ 0\\.05424831021828097\ \(0\)\
\-\ occuring\\:\\ 0\\.05123417267627017\ \(0\)\
\-\ elected\\:\\ 0\\.05006121494151056\ \(0\)\
\-\ specimens\\:\\ 0\\.04903528754024822\ \(0\)\
\-\ benign\\:\\ 0\\.048345087984150846\ \(0\)\
\-\ fibroids\\:\\ 0\\.04494519601468274\ \(0\)\
\-\ wegener\\:\\ 0\\.0446575622457379\ \(0\)\
\-\ av\\:\\ 0\\.04411091163509305\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.04385067640300633\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.04385067640300633\ \(0\)\
\-\ mets\\:\\ 0\\.04035818135947436\ \(0\)\
\-\ transformation\\:\\ 0\\.039714971396839154\ \(0\)\
\-\ modality\\:\\ 0\\.038429377368208256\ \(0\)\
\-\ hamartoma\\:\\ 0\\.038298227029303\ \(0\)\
\-\ emboli\\:\\ 0\\.0379169154257383\ \(0\)\
\-\ ovary\\:\\ 0\\.037793654135865024\ \(0\)\
\-\ infarcts\\:\\ 0\\.03767221900647862\ \(0\)\
\-\ pet\\:\\ 0\\.03676053347278826\ \(0\)\
\-\ septic\\:\\ 0\\.03676053347278826\ \(0\)\
\-\ develop\\:\\ 0\\.03493148797021277\ \(0\)\
\-\ arise\\:\\ 0\\.03467664709258956\ \(0\)\
\-\ metabolic\\:\\ 0\\.03459343093304843\ \(0\)\
\-\ uterus\\:\\ 0\\.03301661214085617\ \(0\)\
\-\ \\%\\:\\ 0\\.03267739398927882\ \(0\)\
\-\ ca\\:\\ 0\\.0326166927624182\ \(0\)\
\-\ embolization\\:\\ 0\\.0326166927624182\ \(0\)\
\-\ as\\:\\ 0\\.03178469276788839\ \(0\)\
\-\ removed\\:\\ 0\\.031579293391037634\ \(0\)\
\-\ gi\\:\\ 0\\.031465448209392816\ \(0\)\
\-\ sarcoma\\:\\ 0\\.031187566638280678\ \(0\)\
\-\ 18\\:\\ 0\\.030406335656278014\ \(0\)\
\-\ metastases\\:\\ 0\\.029924036475762167\ \(0\)\
\-\ multiple\\:\\ 0\\.02950501645047982\ \(0\)\
\-\ nodules\\:\\ 0\\.029037039880350425\ \(0\)\
\-\ pathology\\:\\ 0\\.02866720024690395\ \(0\)\
\-\ malformation\\:\\ 0\\.027937267643494915\ \(0\)\
\-\ malignancy\\:\\ 0\\.027066308834438654\ \(0\)\
\-\ activity\\:\\ 0\\.02627907072771753\ \(0\)\
\-\ metastasis\\:\\ 0\\.026219240379507597\ \(0\)\
\-\ non\\-contributory\\:\\ 0\\.025869149247597353\ \(0\)\
\-\ breast\\:\\ 0\\.025840638883856987\ \(0\)\
\-\ reported\\:\\ 0\\.025533400414555835\ \(0\)\
\-\ \\(\\:\\ 0\\.02368399102438887\ \(0\)\
\-\ \\)\\:\\ 0\\.02339467842994443\ \(0\)\
\-\ between\\:\\ 0\\.022200783083805277\ \(0\)\
\-\ show\\:\\ 0\\.021501278151570706\ \(0\)\
\-\ renal\\:\\ 0\\.021044881552934994\ \(0\)\
\-\ artery\\:\\ 0\\.020856803214001633\ \(0\)\
\-\ primary\\:\\ 0\\.020749051335210628\ \(0\)\
\-\ pulmonary\\:\\ 0\\.02046352713295134\ \(0\)\
\-\ lymphoma\\:\\ 0\\.02001802159335644\ \(0\)\
\-\ \\,\\:\\ 0\\.019970414669308083\ \(0\)\
\-\ months\\:\\ 0\\.019130666349918585\ \(0\)\
\-\ \\:\\:\\ 0\\.018529095344109264\ \(0\)\
\-\ increased\\:\\ 0\\.01713512116229226\ \(0\)\
\-\ 1\\:\\ 0\\.01666660957344022\ \(0\)\
\-\ can\\:\\ 0\\.015887068462861226\ \(0\)\
\-\ well\\:\\ 0\\.015844925844005337\ \(0\)\
\-\ large\\:\\ 0\\.0153159215723859\ \(0\)\
\-\ after\\:\\ 0\\.014491813136141004\ \(0\)\
\-\ treatment\\:\\ 0\\.014177188193449894\ \(0\)\
\-\ which\\:\\ 0\\.013074955633135646\ \(0\)\
\-\ for\\:\\ 0\\.011952592600700248\ \(0\)\
\-\ from\\:\\ 0\\.010380620599624692\ \(0\)\
\-\ history\\:\\ 0\\.009673889653336749\ \(0\)\
\-\ on\\:\\ 0\\.005933532888241214\ \(0\)\
\-\ of\\:\\ 0\\.0038197967474750305\ \(0\)\
\-\ with\\:\\ 0\\.002877151871062862\ \(0\)\
\-\ \\.\\:\\ 0\\.0011639192163064352\ \(0\)\
